8-K - ARDT - Equibles

UNITED STATES<br><br>SECURITIES AND EXCHANGE COMMISSION<br><br>WASHINGTON, D.C. 20549
	FORM	8-K
CURRENT REPORT<br><br>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Ardent Health, Inc.
(Exact Name of Registrant as Specified in its Charter)		Delaware	001-42180	61-1764793
---	---	---
(State or Other Jurisdiction<br><br>of Incorporation)	(Commission<br><br>File Number)	(I.R.S. Employer<br><br>Identification No.)		340 Seven Springs Way, Suite 100,<br><br>Brentwood, Tennessee	37027
---	---
(Address of Principal Executive Offices)	(Zip Code)

(615) 296-3000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under

any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading<br><br>Symbol(s)	Name of each exchange<br><br>on which registered
Common Stock, $.01 par value per<br><br>share	ARDT	New York Stock Exchange

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act

of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, Ardent Health, Inc. issued a press release announcing its financial results for the third quarter

ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and

is incorporated herein by reference.

The information in this Current Report on Form 8-K furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be

deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically provided in any such

filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits:

Exhibit No.	Exhibit Description
Exhibit 99.1	Press Release, dated November 12, 2025
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed

on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025	ARDENT HEALTH, INC.
	By:	/s/ Alfred Lumsdaine
	Name:	Alfred Lumsdaine
	Title:	Executive Vice President, Chief Financial Officer

ARDT - Q3 25 - 8K - EX99.1 1

Exhibit 99.1

Ardent Health Reports Third Quarter 2025 Results

Brentwood, Tenn. (November 12, 2025) – Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a

leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the

quarter ended September 30, 2025.

Third Quarter 2025 Operating and Financial Summary

All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press

release for definitions of the metrics below and a full list of key operating metrics.

Total Revenue<br><br>$1.58 billion<br><br>8.8% growth Y/Y	Net Loss Attributable<br><br>to Ardent Health<br><br>$23 million
Adjusted EBITDA(1)<br><br>$143 million<br><br>46.3% growth Y/Y	Adjusted EBITDAR(1)<br><br>$184 million
Admissions<br><br>5.8% growth Y/Y	Adjusted Admissions<br><br>2.9% growth Y/Y
Net Patient Service Revenue<br><br>per Adjusted Admission<br><br>5.8% growth Y/Y	Revising 2025 Adjusted EBITDA(1) Guidance<br><br>Reaffirming Total Revenue: $6,200 - $6,450 million<br><br>Revising Adjusted EBITDA(1): $530 - $555 million

(1) Adjusted EBITDA and Adjusted EBITDAR are financial measures that have not been prepared in a manner that complies with U.S. generally accepted

accounting principles ("GAAP"). See "Supplemental Non-GAAP Financial Information" and reconciliations of non-GAAP measures to their most

comparable GAAP financial measures contained later in this press release.

Third Quarter 2025 Results Commentary •"Our third quarter results reflect a continuation of the strong demand trends we saw in the first half of 2025," stated Marty Bonick, President and Chief Executive Officer of Ardent Health. “Admissions grew 5.8%, adjusted admissions increased 2.9% (near the high end of our 2025 guidance of 2-3%), and total surgeries trended positive for the first time this year, rising 1.4%. Additionally, revenue and adjusted EBITDA increased 9% and 46%, respectively, and year-to-date adjusted EBITDA through the third quarter grew 30%. Ardent generated strong operating cash flow of $154 million in 3Q25 compared to $90 million in 3Q24." •"While we continue to execute on our strategic priorities, certain industry headwinds are persisting more than anticipated," added Bonick. "We expected Professional Fee expense growth to moderate this year to the upper-single digit range. First half 2025 results were consistent with that, but Professional Fee growth accelerated to 11% in the third quarter. Additionally, payor denials were more pronounced in the third quarter. These dynamics drove a shortfall to our third quarter adjusted EBITDA projections and we expect fourth quarter earnings to be below our original targets. As a result, we are updating 2025 adjusted EBITDA guidance to $530 - $555 million." •"As part of our IMPACT program, we are taking deliberate, measurable actions to mitigate these industry pressures," continued Bonick. "The company has already undertaken a workforce optimization program and renegotiated key contracts, including with certain payors and agency labor that will start to benefit earnings in the fourth quarter. We have also launched focused initiatives in precision staffing, supply chain discipline, and OR excellence." •"We remain confident in our ability to deliver long-term shareholder value while effectively managing near-term challenges,” stated Bonick. “Our updated 2025 guidance implies revenue and adjusted EBITDA growth of 6% and 9%, respectively, and we are generating significant cash flow. Over the longer-term, Ardent is well positioned to continue growing adjusted EBITDA and expanding margins driven by key pillars including: durable demand, operational efficiencies captured by our IMPACT program, and capital deployment supported by our strong balance sheet with over $600 million of cash and net leverage of 2.5x."

Financial Performance Summary

For the third quarter of 2025:

•Total revenue grew 8.8% year-over-year to $1,577 million. The growth in total revenue resulted primarily from a

2.9% increase in adjusted admissions and 5.8% growth in net patient service revenue per adjusted admission year-

over-year. Excluding the impact of a $43 million reduction to revenue resulting from a change in accounting

estimate, as discussed below, total revenue grew 11.7% year-over-year.

•Net loss attributable to Ardent Health was $23 million, or $0.17 per diluted share, compared to net income

attributable to Ardent Health of $26 million, or $0.19 per diluted share, in the third quarter of 2024.

•Adjusted EBITDA increased 46.3% year-over-year to $143 million.

Two non-recurring items impacted reported third quarter 2025 financial results:

•During the third quarter, a change in accounting estimate resulting from a modification to the technique used to

estimate the collectability of accounts receivable and new information provided by recently completed hindsight

evaluations of historical collection trends resulted in a decrease in revenue of $43 million. During the quarter, the

Company implemented a new revenue accounting system that provided management with additional information

to more precisely estimate the collectability of accounts receivable, particularly with respect to more timely

consideration of payor denial and payment trends. The $43 million adjustment is reflected in total revenue for the

quarter but excluded from adjusted EBITDA.

•During the third quarter, the Company recorded an increase to its professional liability reserves as part of its

periodic review of professional liability claims, with input from its third-party actuary. The increase in reserves

included an adjustment of $54 million attributable to the emergence of adverse prior period claim developments

with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and

2022 in New Mexico for a single provider who the Company no longer employs, as well as consideration of broader

industry trends, including social inflationary pressures. The $54 million adjustment attributable to New Mexico is

excluded from adjusted EBITDA.

Operating Performance Summary

The following table provides a summary of certain key operating metrics for the third quarter of 2025 compared to the

same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics

below and a full list of key operating metrics.

	Three Months Ended September 30,
(Unaudited)	2025	2024	% Change
Adjusted admissions	89,328	86,833	2.9%
Admissions	41,862	39,568	5.8%
Inpatient surgeries	9,732	8,871	9.7%
Outpatient surgeries	22,813	23,220	(1.8%)
Total surgeries	32,545	32,091	1.4%
Emergency room visits	161,198	161,343	(0.1%)
Net patient service revenue per adjusted admission	$17,252	$16,312	5.8%

•Admissions for the third quarter of 2025 increased 5.8% year-over-year, driven by strong inpatient surgery growth.

•Surgeries for the third quarter of 2025 increased 1.4% year-over-year, a modest improvement from declines of 0.7%

and 0.2% in the first and second quarters of 2025, respectively. The total surgery year-over-year increase of 1.4% in the

third quarter of 2025 reflected inpatient surgery growth of 9.7% and an outpatient surgery decline of 1.8%.

1 Lease-adjusted net leverage ratio is defined as the Company's net debt as of September 30, 2025, plus 8x trailing twelve-month real estate investment

trust ("REIT") rent expense as of the end of the third quarter of 2025, divided by trailing twelve-month Adjusted EBITDAR as of September 30, 2025.

Balance Sheet, Cash Flow & Liquidity Update

As of September 30, 2025, the Company had total cash and cash equivalents of $609 million and total debt of $1.1 billion.

The Company’s net leverage ratio as of September 30, 2025 was 1.0x, as calculated under the Company's credit

agreements, and its lease-adjusted net leverage ratio1 was 2.5x, an improvement from 2.7x as of June 30, 2025. At the end

of the third quarter, the Company’s available liquidity was $904 million.

During the third quarter of 2025, net cash provided by operating activities was $154 million, compared to $90 million in the

same prior year period.

2025 Financial Guidance

The Company is reaffirming its full-year 2025 revenue guidance, which at the midpoint is an increase of 6% from 2024.

The Company now expects full-year 2025 adjusted EBITDA of $530 - $555 million, which at the midpoint is an increase of 9%

from 2024. The updated guidance primarily reflects higher Professional Fee expenses and a higher level of payor denials for

the second half of 2025. The accounts receivable and professional liability reserve adjustments were not a factor in revising

adjusted EBITDA guidance.

All guidance is current as of the time provided and is subject to change.

	Full Year 2025 Guidance
(Dollars in millions, except per share amount)	Previous Guidance			New Guidance
Total revenue	$6,200	—	$6,450	$6,200	—	$6,450
Net income attributable to Ardent Health, Inc.	$245	—	$285	$121	—	$146
Adjusted EBITDA	$575	—	$615	$530	—	$555
Rent expense payable to REITs	$164	—	$164	$164	—	$164
Diluted earnings per share	$1.73	—	$2.01	$0.85	—	$1.03
Adjusted admissions growth	2.0%	—	3.0%	2.0%	—	3.0%
Net patient service revenue per adjusted admission growth	2.1%	—	4.4%	2.1%	—	4.4%
Capital expenditures	$215	—	$235	$215	—	$235

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown

uncertainties and risks, including those set forth below under the heading "Forward-Looking Statements." The Company

does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of

debt, legal claim costs (benefits) and impairments of long-lived assets. The Company does not believe that it can forecast

these items with sufficient accuracy because of the inherent difficulty of forecasting the timing or amount of various items

that have not yet occurred and are out of the Company’s control or cannot be reasonably predicted.

Third Quarter 2025 Results Conference Call

The Company will host a conference call to discuss its third quarter financial results on November 13, 2025, at 9:00 a.m.

Eastern Time. A webcast of the conference call will be available in the Investor Relations section of the Company’s

corporate website at https://ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the

scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

United States Live: 1-888-596-4144

International Live: 1-646-968-2525

Access Code: 4437657

To listen to a replay of the teleconference, which will be available through November 27, 2025:

United States Replay: 1-800-770-2030

International Replay: 1-609-800-9909

Access Code: 4437657

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S.

With a focus on people and investments in innovative services and technologies, Ardent is passionate about making

healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute

care hospitals and approximately 280 sites of care with over 1,900 employed and affiliated providers across six states. For

more information, please visit ardenthealth.com.

Investor Contact:<br><br>Dave Styblo, CFA<br><br>Investor.Relations@ardenthealth.com<br><br>(615) 296-3016
Media Contact:<br><br>Rebecca Kirkham<br><br>rebecca.kirkham@ardenthealth.com<br><br>(615) 296-3000

Supplemental Non-GAAP Financial Information

We have included certain non-GAAP financial measures in this press release, including Adjusted EBITDA, Adjusted EBITDA

margin, and Adjusted EBITDAR. We define these terms as follows:

•Adjusted EBITDA and Adjusted EBITDA Margin. Adjusted EBITDA is defined as net income plus (i) provision for income

taxes, (ii) interest expense and (iii) depreciation and amortization expense (or EBITDA), as adjusted to deduct

noncontrolling interest earnings, and excludes the effects of loss on extinguishment and modification of debt; other

non-operating losses (gains); recoveries from the cybersecurity incident in November 2023 (the "Cybersecurity

Incident"), net of incremental information technology and litigation costs; restructuring, exit and acquisition-related

costs; change in accounting estimate; New Mexico professional liability accrual; expenses incurred in connection with

the implementation of our integrated health information technology system provided by Epic Systems; equity-based

compensation expense; and (income) loss from disposed operations. Adjusted EBITDA margin is defined as Adjusted

EBITDA divided by total revenue.

Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP performance measures used by our management and

external users of our financial statements, such as investors, analysts, lenders, rating agencies and other interested

parties, to evaluate companies in our industry. Adjusted EBITDA and Adjusted EBITDA margin are performance

measures that are not prepared in accordance with GAAP and are presented in this press release because our

management considers them important analytical indicators commonly used within the healthcare industry to evaluate

financial performance and allocate resources. Further, our management believes that Adjusted EBITDA and Adjusted

EBITDA margin are useful financial metrics to assess our operating performance from period to period by excluding

certain material non-cash items and unusual or non-recurring items that we do not expect to continue in the future and

certain other adjustments we believe are not reflective of our ongoing operations and our performance.

Because not all companies use identical calculations, our presentation of Adjusted EBITDA and Adjusted EBITDA margin

may not be comparable to other similarly titled measures of other companies. While we believe these are useful

supplemental performance measures for investors and other users of our financial information, you should not

consider Adjusted EBITDA and Adjusted EBITDA margin in isolation or as a substitute for net income or any other items

calculated in accordance with GAAP. Adjusted EBITDA and Adjusted EBITDA margin have inherent material limitations

as performance measures, because they add back certain expenses to net income, resulting in those expenses not

being taken into account in the performance measures. We have borrowed money, so interest expense is a necessary

element of our costs. Because we have material capital and intangible assets, depreciation and amortization expense

are necessary elements of our costs. Likewise, the payment of taxes is a necessary element of our operations. Because

Adjusted EBITDA and Adjusted EBITDA margin exclude these and other items, they have material limitations as

measures of our performance.

•Adjusted EBITDAR. Adjusted EBITDAR is defined as Adjusted EBITDA further adjusted to add back rent expense payable

to REITs, which consists of rent expense pursuant to the master lease agreement (the "Ventas Master Lease") with

Ventas, Inc. ("Ventas"), lease agreements associated with the MOB Transactions (defined below) and a lease

arrangement with Medical Properties Trust, Inc. ("MPT") for the Hackensack Meridian Mountainside Medical Center.

Adjusted EBITDAR is a commonly used non-GAAP valuation measure used by our management, research analysts,

investors and other interested parties to evaluate and compare the enterprise value of different companies in our

industry. Adjusted EBITDAR excludes: (1) certain material noncash items and unusual or non-recurring items that we do

not expect to continue in the future; (2) certain other adjustments that do not impact our enterprise value; and (3) rent

expense payable to our REITs. We operate 30 acute care hospitals, 12 of which we lease from two REITs, Ventas and

MPT, pursuant to long-term lease agreements. Additionally, during 2022, we completed the sale of 18 medical office

buildings to Ventas in exchange for $204.0 million and concurrently entered into agreements to lease the real estate

back from Ventas over a 12-year initial term with eight options to renew for additional five-year terms (the "MOB

Transactions"). Our management views the long-term lease agreements with Ventas and MPT, as well as the MOB

Transactions, as more like financing arrangements than true operating leases, with the rent payable to such REITs being

similar to interest expense. As a result, our capital structure is different than many of our competitors, especially those

whose real estate portfolio is predominately owned and not leased. Excluding the rent payable to such REITs allows

investors to compare our enterprise value to those of other healthcare companies without regard to differences in

capital structures, leasing arrangements and geographic markets, which can vary significantly among companies. Our

management also uses Adjusted EBITDAR as one measure in determining the value of prospective acquisitions or

divestitures. Finally, financial covenants in certain of our lease agreements, including the Ventas Master Lease, use

Adjusted EBITDAR as a measure of compliance. Adjusted EBITDAR does not reflect our cash requirements for leasing

commitments. As such, our presentation of Adjusted EBITDAR should not be construed as a performance or liquidity

measure.

Because not all companies use identical calculations, our presentation of Adjusted EBITDAR may not be comparable to

other similarly titled measures of other companies. While we believe this is a useful supplemental valuation measure

for investors and other users of our financial information, you should not consider Adjusted EBITDAR in isolation or as a

substitute for net income or any other items calculated in accordance with GAAP. Adjusted EBITDAR has inherent

material limitations as a valuation measure, because it adds back certain expenses to net income, resulting in those

expenses not being taken into account in the valuation measure. The payment of taxes and rent is a necessary element

of our valuation. Because Adjusted EBITDAR excludes these and other items, it has material limitations as a measure of

our valuation.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the U.S. federal securities laws. These

forward-looking statements include, but are not limited to, statements other than statements of historical facts, including,

among others, statements relating to our future financial performance, our business prospects and strategy, anticipated

financial position, liquidity and capital needs, the industry in which we operate and other similar matters. Words such as

"anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "could," "would," "will," "may,"

"can," "continue," "potential," "should" and the negative of these terms or other comparable terminology often identify

forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject

to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-

looking statements. Factors, risks, and uncertainties that could cause actual outcomes and results to be materially different

from those contemplated include, among others: (1) general economic and business conditions, both nationally and in the

regions in which we operate, including the impact of challenging macroeconomic conditions and inflationary pressures,

current geopolitical instability, and impacts from the imposition of, or changes in, tariffs, as well as the potential impact on

us of the federal government shutdown or other uncertain political, financial, credit and capital conditions; (2) possible

reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment

programs, Medicaid waiver programs or state directed payments, that could have an adverse effect on our revenues and

business; (3) reduction in the reimbursement rates paid by commercial payors, increased reimbursement denials or

payment delays by commercial payors, our inability to retain and negotiate favorable contracts with private third party

payors, or an increasing volume of uninsured or underinsured patients; (4) effects of changes in healthcare policy or

legislation, including the One Big Beautiful Bill Act (the "OBBBA") and any other reforms that have or may be undertaken by

the current presidential administration, and legal and regulatory restrictions on our hospitals that have physician owners;

(5) the ability to achieve operating and financial targets, develop and execute mitigation plans to offset to the extent

possible impacts from the OBBBA, the scheduled expiration of temporary enhanced subsidies for individuals eligible to

purchase insurance coverage through health insurance marketplaces and imposition of tariffs, attain expected levels of

patient volumes and revenues, and control the costs of providing services; (6) security threats, catastrophic events and

other disruptions affecting our, our service providers’ or our joint venture ("JV") partners’ information technology and

related systems, which have adversely affected, and could in the future adversely affect, our relationships with patients and

business partners and subject us to legal claims and liabilities, reputational harm and business disruption and adversely

affect our financial condition; (7) the highly competitive nature of the healthcare industry and continued industry trends

towards clinical transparency and value-based purchasing may impact our competitive position; (8) inability to recruit and

retain quality physicians, as well as increasing cost to contract with hospital-based physicians; (9) changes to physician

utilization practices and treatment methodologies and other factors outside our control that impact demand for medical

services and may reduce our revenues and ability to grow profitability; (10) the effects related to the sequestration

spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential

for future deficit reduction legislation; (11) continued industry trends toward value-based purchasing, third party payor

consolidation and care coordination among healthcare providers; (12) inability to successfully complete acquisitions or

strategic JVs or inability to realize all of the anticipated benefits; (13) liabilities because of professional liability and other

claims brought against our hospitals, physician practices, outpatient facilities or other business operations; (14) exposure to

certain risks and uncertainties by the JVs through which we conduct a significant portion of our operations, including

anticipated synergies of past acquisitions and the risk that transactions may not receive necessary government clearances;

(15) failure to obtain drugs and medical supplies at favorable prices or sufficient volumes; (16) operational, legal and

financial risks associated with outsourcing functions to third parties; (17) our facilities are heavily concentrated in Texas and

Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states; (18)

negative impact of severe weather, climate change, and other factors beyond our control, which could restrict patient

access to care or cause one or more facilities to close temporarily or permanently; (19) risks related to the Master Lease

with Ventas ("Ventas Master Lease") and its restrictions and limitations on our business; (20) the impact of our significant

indebtedness and the ability to refinance such indebtedness on acceptable terms; (21) our failure to comply with complex

laws and regulations applicable to the healthcare industry or to adjust our operations in response to changing laws and

regulations; (22) the impact of governmental claims or governmental investigations, payor audits and litigation brought

against our hospitals, physician practices, outpatient facilities or other business operations; (23) actual or perceived failures

to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements; (24)

the impact of a deterioration of public health conditions associated with a future pandemic, epidemic or outbreak of

infectious disease; (25) inability to or delay in building, acquiring, selling, renovating or expanding our healthcare facilities;

(26) failure to comply with federal and state laws relating to Medicare and Medicaid enrollment, permit, licensing and

accreditation requirements; (27) the results of our efforts to use technology, including artificial intelligence and machine

learning, to drive efficiencies, better outcomes and an enhanced patient experience; (28) our status as a controlled

company; (29) conflicts of interest between our controlling stockholder and other holders of our common stock; and (30)

other risk factors described in our filings with the Securities and Exchange Commission.

Many of the important factors that will determine these results are beyond our ability to control or predict. You are

cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this press

release. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to

these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the

occurrence of unanticipated events. All references to "Company," "Ardent Health," "Ardent," "we," "our" and "us" as used

throughout this release refer to Ardent Health, Inc. and its affiliates, unless stated otherwise or indicated by context.

Ardent Health, Inc.

Condensed Consolidated Income Statements

(Unaudited; dollars in thousands, except per share amounts)

	Three Months Ended September 30,
	2025	2024
	Amount	Amount
Total revenue	1,576,746	1,449,817
Expenses:
Salaries and benefits	676,962	635,223
Professional fees	305,083	274,223
Supplies	275,881	251,862
Rents and leases	26,386	26,410
Rents and leases, related party	38,106	37,249
Other operating expenses	198,714	117,700
Interest expense	13,914	14,629
Depreciation and amortization	39,156	36,771
Loss on extinguishment and modification of debt	7,344	1,898
Other non-operating gains	(2,597)	(2,807)
Total operating expenses	1,578,949	1,392,750
(Loss) income before income taxes	(2,203)	57,067
Income tax (benefit) expense	(3,410)	11,062
Net income	1,207	46,005
Net income attributable to noncontrolling interests	24,685	19,683
Net (loss) income attributable to Ardent Health, Inc.	(23,478)	26,322
Net (loss) income per share:
Basic	(0.17)	0.19
Diluted	(0.17)	0.19
Weighted-average common shares outstanding:
Basic	141,226,862	137,107,595
Diluted	141,226,862	137,542,995

All values are in US Dollars.

Ardent Health, Inc.

Condensed Consolidated Income Statements

(Unaudited; dollars in thousands, except per share amounts)

	Nine Months Ended September 30,
	2025	2024
	Amount	Amount
Total revenue	4,719,260	4,359,783
Expenses:
Salaries and benefits	2,006,311	1,880,790
Professional fees	882,952	810,820
Supplies	805,375	769,034
Rents and leases	81,972	76,251
Rents and leases, related party	113,975	111,413
Other operating expenses	493,179	354,851
Interest expense	42,819	52,050
Depreciation and amortization	114,666	108,434
Loss on extinguishment and modification of debt	7,344	3,388
Other non-operating gains	(23,320)	(3,062)
Total operating expenses	4,525,273	4,163,969
Income before income taxes	193,987	195,814
Income tax expense	38,114	36,997
Net income	155,873	158,817
Net income attributable to noncontrolling interests	65,018	62,678
Net income attributable to Ardent Health, Inc.	90,855	96,139
Net income per share:
Basic	0.65	0.74
Diluted	0.64	0.74
Weighted-average common shares outstanding:
Basic	140,569,409	129,877,510
Diluted	141,242,065	130,022,643

All values are in US Dollars.

Ardent Health, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited; in thousands)

	Nine Months Ended<br><br>September 30,
	2025	2024
Cash flows from operating activities:
Net income	$155,873	$158,817
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	114,666	108,434
Other non-operating losses	1,275	—
Loss on extinguishment and modification of debt	515	2,158
Amortization of deferred financing costs and debt discounts	3,568	4,235
Deferred income taxes	14,884	1,690
Equity-based compensation	30,183	8,873
(Income) loss from non-consolidated affiliates	(1,409)	2,160
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable	16,594	77,284
Inventories	(6,308)	(2,545)
Prepaid expenses and other current assets	(47,361)	(21,189)
Accounts payable and other accrued expenses and liabilities	(15,716)	(132,031)
Accrued salaries and benefits	(19,689)	(12,429)
Net cash provided by operating activities	247,075	195,457
Cash flows from investing activities:
Investment in acquisitions, net of cash acquired	—	(8,044)
Purchases of property and equipment	(127,909)	(106,234)
Other	(92)	(738)
Net cash used in investing activities	(128,001)	(115,016)
Cash flows from financing activities:
Proceeds from insurance financing arrangements	15,607	10,797
Proceeds from long-term debt	—	3,600
Payments of principal on insurance financing arrangements	(10,751)	(7,370)
Payments of principal on long-term debt	(4,506)	(106,335)
Debt issuance costs	(2,573)	(2,450)
Payments of initial public offering costs	—	(8,636)
Distributions to noncontrolling interests	(62,366)	(53,138)
Other	(1,829)	—
Net cash (used in) provided by financing activities	(66,418)	45,124
Net increase in cash and cash equivalents	52,656	125,565
Cash and cash equivalents at beginning of period	556,785	437,577
Cash and cash equivalents at end of period	$609,441	$563,142	Supplemental Cash Flow Information:
---	---	---
Non-cash purchases of property and equipment	$13,509	$5,546
Offering costs not yet paid	$—	$898

Ardent Health, Inc.

Condensed Consolidated Balance Sheets

(Unaudited; dollars in thousands, except per share amounts)

	September 30,<br><br>2025(1)	December 31,<br><br>2024 (1)
Assets
Current assets:
Cash and cash equivalents	$609,441	$556,785
Accounts receivable	729,414	743,031
Inventories	121,594	115,093
Prepaid expenses	130,882	113,749
Other current assets	366,129	304,093
Total current assets	1,957,460	1,832,751
Property and equipment, net	887,984	861,899
Operating lease right of use assets	292,206	248,040
Operating lease right of use assets, related party	919,124	929,106
Goodwill	877,509	852,084
Other intangible assets	90,090	76,930
Deferred income taxes	18,406	12,321
Other assets	111,594	142,969
Total assets	$5,154,373	$4,956,100
Liabilities and Equity
Current liabilities:
Current installments of long-term debt	$19,342	$9,234
Accounts payable	381,853	401,249
Accrued salaries and benefits	275,607	295,117
Other accrued expenses and liabilities	266,352	239,824
Total current liabilities	943,154	945,424
Long-term debt, less current installments	1,087,023	1,085,818
Long-term operating lease liability	260,748	221,443
Long-term operating lease liability, related party	908,482	919,313
Self-insured liabilities	260,621	227,048
Other long-term liabilities	62,498	34,697
Total liabilities	3,522,526	3,433,743
Redeemable noncontrolling interests	(1,489)	1,158
Equity:
Preferred stock, par value $0.01 per share; 50,000,000 shares authorized; no shares issued and<br><br>outstanding	—	—
Common stock, par value $0.01 per share; 750,000,000 shares authorized; 143,169,831 shares issued and<br><br>outstanding as of September 30, 2025 and 142,747,818 shares issued and outstanding as of December 31,<br><br>2024	1,432	1,428
Additional paid-in capital	782,765	754,415
Accumulated other comprehensive (loss) income	(2,634)	9,737
Retained earnings	456,651	365,796
Equity attributable to Ardent Health, Inc.	1,238,214	1,131,376
Noncontrolling interests	395,122	389,823
Total equity	1,633,336	1,521,199
Total liabilities and equity	$5,154,373	$4,956,100

(1)As of September 30, 2025 and December 31, 2024, the unaudited condensed consolidated balance sheet included total liabilities of consolidated variable interest

entities of $309.0 million and $306.4 million, respectively. Refer to Note 2 of the Company's unaudited condensed consolidated financial statements included in its

Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025 for further discussion.

Ardent Health, Inc.

Operating Statistics

(Unaudited)

	Three Months Ended September 30,			Nine Months Ended September 30,
	2025	%<br><br>Change	2024	2025	%<br><br>Change	2024
Total revenue (in thousands)	$1,576,746	8.8%	$1,449,817	$4,719,260	8.2%	$4,359,783
Hospitals operated (at period end) (1)	30	0.0%	30	30	0.0%	30
Licensed beds (at period end) (2)	4,281	(0.1)%	4,287	4,281	(0.1)%	4,287
Utilization of licensed beds (3)	49%	6.5%	46%	50%	8.7%	46%
Admissions (4)	41,862	5.8%	39,568	124,786	6.7%	116,995
Adjusted admissions (5)	89,328	2.9%	86,833	261,031	2.4%	254,909
Inpatient surgeries (6)	9,732	9.7%	8,871	28,822	7.4%	26,829
Outpatient surgeries (7)	22,813	(1.8)%	23,220	67,385	(2.6)%	69,201
Total surgeries	32,545	1.4%	32,091	96,207	0.2%	96,030
Emergency room visits (8)	161,198	(0.1)%	161,343	479,069	0.8%	475,212
Patient days (9)	193,558	6.3%	182,023	584,510	8.2%	540,196
Total encounters (10)	1,577,281	6.4%	1,482,655	4,519,815	5.0%	4,304,097
Average length of stay (11)	4.62	0.4%	4.60	4.68	1.3%	4.62
Net patient service revenue per adjusted admission (12)	$17,252	5.8%	$16,312	$17,745	5.7%	$16,784

(1)Hospitals operated (at period end). This metric represents the total number of hospitals operated by us at the end of the applicable period, irrespective of

whether the hospital real estate is (i) owned by us, (ii) leased by us or (iii) held through a controlling interest in a JV. This metric includes the managed

clinical operations of the hospital at UT Health North Campus in Tyler, Texas ("UT Health North Campus Tyler"), a hospital owned by The University of

Texas Health Science Center at Tyler ("UTHSCT"), an affiliate of The University of Texas System. Since we only manage the clinical operations of UT Health

North Campus Tyler, the financial results of such entity are not consolidated under Ardent Health, Inc.

On April 30, 2024, we closed UT Health East Texas Specialty Hospital, a long-term acute care hospital with 36 licensed patient beds (the “LTAC Hospital”) in

Tyler, Texas. The LTAC Hospital's inventory and fixed assets were transferred or repurposed to be used by our other hospitals.

(2)Licensed beds (at period end). This metric represents the total number of beds for which the appropriate state agency licenses a facility, regardless of

whether the beds are actually available for patient use.

(3)Utilization of licensed beds. This metric represents a measure of the actual utilization of our inpatient facilities, computed by (i) dividing patient days by

the number of days in each period, and (ii) further dividing that number by average licensed beds, which is calculated by dividing total licensed beds (at

period end) by the number of days in the period, multiplied by the number of days in the period the licensed beds were in existence.

(4)Admissions. This metric represents the number of patients admitted for inpatient treatment during the applicable period.

(5)Adjusted admissions. This metric is used by management as a general measure of combined inpatient and outpatient volume. Adjusted admissions

provides management with a key performance indicator that considers both inpatient and outpatient volumes by applying an inpatient volume measure

(admissions) to a ratio of gross inpatient and outpatient revenue to gross inpatient revenue. Gross inpatient and outpatient revenue reflect gross inpatient

and outpatient charges prior to estimated contractual adjustments, uninsured discounts, implicit price concessions, and other discounts. The calculation of

adjusted admissions is summarized as follows:

Adjusted Admissions	=	Admissions	x	(Gross Inpatient Revenue + Gross Outpatient Revenue)
				Gross Inpatient Revenue

(6)Inpatient surgeries. This metric represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management, c-

sections, and certain diagnostic procedures are excluded from inpatient surgeries.

(7)Outpatient surgeries. This metric represents the number of surgeries performed on patients who have not been admitted to our hospitals. Pain

management, c-sections, and certain diagnostic procedures are excluded from outpatient surgeries.

(8)Emergency room visits. This metric represents the total number of patients provided with emergency room treatment during the applicable period.

(9)Patient days. This metric represents the total number of days of care provided to patients admitted to our hospitals during the applicable period.

(10)Total encounters. This metric represents the total number of events where healthcare services are rendered resulting in a billable event during the

applicable period. This includes both hospital and ambulatory patient interactions.

(11)Average length of stay. This metric represents the average number of days admitted patients stay in our hospitals.

(12)Net patient service revenue per adjusted admission. This metric represents net patient service revenue divided by adjusted admissions for the applicable

period. Net patient service revenue reflects gross inpatient and outpatient charges less estimated contractual adjustments, uninsured discounts, implicit

price concessions, and other discounts.

Ardent Health, Inc.

Supplemental Non-GAAP Disclosures

(Unaudited; in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Net income	$1,207	$46,005	$155,873	$158,817
Adjusted EBITDA Addbacks:
Income tax (benefit) expense	(3,410)	11,062	38,114	36,997
Interest expense	13,914	14,629	42,819	52,050
Depreciation and amortization	39,156	36,771	114,666	108,434
Noncontrolling interest earnings	(24,685)	(19,683)	(65,018)	(62,678)
Loss on extinguishment and modification of debt	7,344	1,490	7,344	3,388
Other non-operating losses (gains) (1)	353	47	1,130	(208)
Cybersecurity Incident recoveries, net (2)	(2,950)	(4,976)	(22,655)	(4,976)
Restructuring, exit and acquisition-related costs (3)	3,040	3,796	7,944	11,694
Change in accounting estimate (4)	43,298	—	43,298	—
New Mexico professional liability accrual (5)	54,468	—	54,468	—
Epic expenses (6)	1,620	485	2,904	1,500
Equity-based compensation	9,674	8,135	30,183	8,873
(Income) loss from disposed operations	(11)	3	22	1,989
Adjusted EBITDA	$143,018	$97,764	$411,092	$315,880
Total revenue	$1,576,746	$1,449,817	$4,719,260	$4,359,783
Adjusted EBITDA margin	9.1%	6.7%	8.7%	7.2%

(1)Other non-operating losses (gains) include losses and gains realized on certain non-recurring events or events that are non-operational in nature.

(2)Cybersecurity Incident recoveries, net represent insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information

technology and litigation costs.

(3)Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work force reductions of $2.7

million and $3.2 million for the three months ended September 30, 2025 and 2024, respectively, and $6.0 million and $10.1 million for the nine months

ended September 30, 2025 and 2024, respectively, (ii) penalties and costs incurred for terminating pre-existing contracts at acquired facilities of $0.2 million

for the three months ended September 30, 2024, and $0.4 million and $0.6 million for the nine months ended September 30, 2025 and 2024, respectively,

and (iii) third-party professional fees and expenses, salaries and benefits, and other internal expenses incurred in connection with potential and completed

acquisitions of $0.3 million and $0.4 million for the three months ended September 30, 2025 and 2024, respectively, and $1.5 million and $1.0 million for the

nine months ended September 30, 2025 and 2024, respectively.

(4)Change in accounting estimate reflects the reduction in total revenue of $42.6 million and its $0.7 million impact on noncontrolling interest earnings as a

result of a change in its accounting estimate of the collectability of accounts receivable as further described above.

(5)During the three and nine months ended September 30, 2025, we recorded an increase in our professional liability reserves of $47.2 million. This adjustment

included an increase of $54.5 million for adverse prior-period claim developments in New Mexico primarily attributable to recent claim settlements and

ongoing litigation arising from the actions of a single provider who was employed between 2019 and 2022 and as further described above.

(6)Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology system. These costs

included (i) professional fees of $0.2 million and $0.5 million for the three months ended September 30, 2025 and 2024, respectively, and $1.5 million for

each of the nine months ended September 30, 2025 and 2024, (ii) salaries and benefits of $1.3 million for each of the three and nine months ended

September 30, 2025, and (iii) other expenses related to one-time training and onboarding support costs of $0.1 million for each of the three and nine months

ended September 30, 2025. Epic expenses do not include ongoing operating costs of the Epic system.

Ardent Health, Inc.

Supplemental Non-GAAP Disclosures

(Unaudited; in thousands)

	Three Months Ended<br><br>September 30, 2025	Nine Months Ended<br><br>September 30, 2025
Net income	$1,207	$155,873
Adjusted EBITDAR Addbacks:
Income tax expense	(3,410)	38,114
Interest expense	13,914	42,819
Depreciation and amortization	39,156	114,666
Noncontrolling interest earnings	(24,685)	(65,018)
Loss on extinguishment and modification of debt	7,344	7,344
Other non-operating losses (1)	353	1,130
Cybersecurity Incident recoveries, net (2)	(2,950)	(22,655)
Restructuring, exit and acquisition-related costs (3)	3,040	7,944
Change in accounting estimate (4)	43,298	43,298
New Mexico professional liability accrual (5)	54,468	54,468
Epic expenses (6)	1,620	2,904
Equity-based compensation	9,674	30,183
(Income) loss from disposed operations	(11)	22
Rent expense payable to REITs (7)	40,961	122,522
Adjusted EBITDAR	$183,979	$533,614

(1)Other non-operating losses include losses realized on certain non-recurring events or events that are non-operational in nature.

(2)Cybersecurity Incident recoveries, net represent insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information

technology and litigation costs.

(3)Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work force reductions of

$2.7 million and $6.0 million for the three and nine months ended September 30, 2025, respectively, (ii) penalties and costs incurred for terminating pre-

existing contracts at acquired facilities of $0.4 million for the nine months ended September 30, 2025, and (iii) third-party professional fees and expenses,

salaries and benefits, and other internal expenses incurred in connection with potential and completed acquisitions of $0.3 million and $1.5 million for the

three and nine months ended September 30, 2025, respectively.

(4)Change in accounting estimate reflects the reduction in total revenue of $42.6 million and its $0.7 million impact on noncontrolling interest earnings as a

result of a change in its accounting estimate of the collectability of accounts receivable as further described above.

(5)During the three and nine months ended September 30, 2025, we recorded an increase in our professional liability reserves of $47.2 million. This adjustment

included an increase of $54.5 million for adverse prior-period claim developments in New Mexico primarily attributable to recent claim settlements and

ongoing litigation arising from the actions of a single provider who was employed between 2019 and 2022 and as further described above.

(6)Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology system. These costs

included (i) professional fees of $0.2 million and $1.5 million for the three and nine months ended September 30, 2025, respectively, (ii) salaries and

benefits of $1.3 million for each of the three and nine months ended September 30, 2025, and (iii) other expenses related to one-time training and

onboarding support costs of $0.1 million for each of the three and nine months ended September 30, 2025. Epic expenses do not include ongoing operating

costs of the Epic system.

(7)Rent expense payable to REITs for the three and nine months ended September 30, 2025 consists of rent expense of $38.1 million and $114.0 million,

respectively, related to the Ventas Master Lease and other lease agreements with Ventas for medical office buildings and rent expense of $2.9 million and

$8.5 million, respectively, related to a lease arrangement with MPT for the lease of Hackensack Meridian Mountainside Medical Center.

Ardent Health, Inc.

Supplemental Non-GAAP Disclosures

(Unaudited; in millions)

	Guidance for the Full Year Ending<br><br>December 31, 2025
	Low	High
Net income	$207	$234
Adjusted EBITDA Addbacks:
Income tax expense	51	58
Interest expense	58	56
Depreciation and amortization	156	153
Noncontrolling interest earnings	(86)	(88)
Loss on extinguishment and modification of debt	7	7
Other non-operating gain	1	1
Cybersecurity Incident recoveries, net (1)	(23)	(23)
Restructuring, exit and acquisition-related costs	14	13
Change in accounting estimate (2)	43	43
New Mexico professional liability accrual (3)	54	54
Epic expenses	4	4
Enterprise system conversion costs	3	3
Equity-based compensation	41	40
Adjusted EBITDA	$530	$555

(1)Cybersecurity Incident recoveries, net represent insurance recovery proceeds associated with the Cybersecurity Incident, net of incremental information

technology and litigation costs.

(2)Change in accounting estimate reflects the reduction in total revenue of $42.6 million and its $0.7 million impact on noncontrolling interest earnings as a

result of a change in its accounting estimate of the collectability of accounts receivable as further described above.

(3)During the three and nine months ended September 30, 2025, we recorded an increase in our professional liability reserves of $47.2 million. This adjustment

included an increase of $54.5 million for adverse prior-period claim developments in New Mexico primarily attributable to recent claim settlements and

ongoing litigation arising from the actions of a single provider who was employed between 2019 and 2022 and as further described above.